Patents by Inventor Fajun Nan

Fajun Nan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pentacyclic triterpene compound and preparation method therefor, and pharmaceutical composition and use thereof
    Patent number: 11192916
    Abstract: Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: December 7, 2021
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Xin Xie, Chenlu Zhang, Shimeng Guo, Yangming Zhang, Siwei Wang
  • GPR84 receptor antagonist and use thereof
    Patent number: 11098071
    Abstract: The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 24, 2021
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Xin Xie, Linhai Chen, Qing Zhang, Yufeng Xiao, Hui Yang
  • Aryl-2,2?-tandem bisthiazole compound and preparation method and use thereof
    Patent number: 10766889
    Abstract: The invention describes an aryl-2,2?-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2?-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: September 8, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Fajun Nan, Jia Li, Jian Ding, Meiyu Geng, Yangming Zhang, Yi Chen, Yubo Zhou, Chaojun Gong, Mingbo Su, Anhui Gao
  • PENTACYCLIC TRITERPENE COMPOUND AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20200231623
    Abstract: Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors.
    Type: Application
    Filed: September 17, 2018
    Publication date: July 23, 2020
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun NAN, Xin XIE, Chenlu ZHANG, Shimeng GUO, Yangming ZHANG, Siwei WANG
  • GPR84 RECEPTOR ANTAGONIST AND USE THEREOF
    Publication number: 20200010492
    Abstract: The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.
    Type: Application
    Filed: February 28, 2016
    Publication date: January 9, 2020
    Inventors: Fajun NAN, Xin XIE, Linhai CHEN, Qing ZHANG, Yufeng XIAO, Hui YANG
  • Fatty acid compound, preparation method therefor and use therefor
    Patent number: 10414713
    Abstract: The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: September 17, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Jia Li, Jingya Li, Mei Zhang, Zhifu Xie, Jingtao Wang, Dongdong Guo
  • ARYL-2,2'-TANDEM BISTHIAZOLE COMPOUND AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20190211005
    Abstract: The invention describes an aryl-2,2?-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2?-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.
    Type: Application
    Filed: August 24, 2017
    Publication date: July 11, 2019
    Inventors: Fajun NAN, Jia LI, Jian DING, Meiyu GENG, Yangming ZHANG, Yi CHEN, Yubo ZHOU, Chaojun GONG, Mingbo SU, Anhui GAO
  • KCNQ potassium channel agonist, and preparation method therefor and use thereof
    Patent number: 10316008
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: June 11, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Yangming Zhang, Haining Hu, Haiyan Xu, Huanan Liu, Xiaoping Pi
  • Tricyclic analogues, preparation method and uses thereof
    Patent number: 10278962
    Abstract: The present invention relates to a series of analogs of natural product Pyripyropene A represented by general formula I and a preparation method and use thereof. More particularly, the present invention relates to analogs of the natural product Pyripyropene A, a preparation method and use thereof as the acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors for the treatment of cardiovascular diseases such as atherosclerosis and the like.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 7, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Boliang Li, Yang Zhan, Xiaowei Zhang, Ying Xiong, Xichan Hu, Yangming Zhang
  • FATTY ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREFOR
    Publication number: 20190039989
    Abstract: The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes.
    Type: Application
    Filed: February 20, 2017
    Publication date: February 7, 2019
    Inventors: Fajun NAN, Jia LI, Jingya LI, Mei ZHANG, Zhifu XIE, Jingtao WANG, Dongdong GUO
  • One class of pyrazolone compounds and use thereof
    Patent number: 10196389
    Abstract: Provided are a class of pyrazolone compounds and a use thereof. In particular, a compound represented by formula I is provided, wherein the definition of each variable group is as described in the description. The compounds of formula (I) have a direct AMPK-activating activity and can significantly promote the phosphorylation of AMPK and ACC of L6 myocytes and HepG2 cells in a dose-dependent manner.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: February 5, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Jia Li, Jingya Li, Mei Zhang, Dakai Chen, Lina Zhang, Runtao Zhang, Zhifu Xie
  • KCNQ potassium channel agonists, method of preparation and method of use thereof
    Patent number: 10077245
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: September 18, 2018
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Yangming Zhang, Haining Hu, Haiyan Xu, Huanan Liu, Xiaoping Pi
  • COMPOUNDS HAVING AGONISTIC EFFECT AGAINST GPR84, PREPARATION METHOD FOR COMPOUNDS AND USE OF COMPOUNDS
    Publication number: 20180237399
    Abstract: The present invention relates to a class of compounds represented by the formula I, or pharmaceutically acceptable salts thereof, methods for their preparation, and application as small molecule tools that function as GPR84 agonists, and their use in preparing a medicament for the treatment of septicemia.
    Type: Application
    Filed: November 1, 2016
    Publication date: August 23, 2018
    Inventors: Fajun NAN, Xin XIE, Yang LIU, Qing ZHANG, Linhai CHEN, Hui YANG
  • NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20180134677
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Yangming Zhang, Haining Hu, Haiyan Xu, Huanan Liu, Xiaoping Pi
  • TRICYCLIC ANALOGUES, PREPARATION METHOD AND USES THEREOF
    Publication number: 20180064696
    Abstract: The present invention relates to a series of analogues of natural product Pyripyropene A represented by general formula I and a preparation method and use thereof. More particularly, the present invention relates to analogues of the natural product Pyripyropene A, a preparation method and use thereof as the acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors for the treatment of cardiovascular diseases such as atherosclerosis and the like.
    Type: Application
    Filed: March 3, 2016
    Publication date: March 8, 2018
    Inventors: Fajun NAN, Boliang LI, Yang ZHAN, Xiaowei ZHANG, Ying XIONG, Xichan HU, Yangming ZHANG
  • ONE CLASS OF PYRAZOLONE COMPOUNDS AND USE THEREOF
    Publication number: 20170247371
    Abstract: Provided are a class of pyrazolone compounds and a use thereof. In particular, a compound represented by formula I is provided, wherein the definition of each variable group is as described in the description. The compounds of formula (I) have a direct AMPK-activating activity and can significantly promote the phosphorylation of AMPK and ACC of L6 myocytes and HepG2 cells in a dose-dependent manner.
    Type: Application
    Filed: July 14, 2015
    Publication date: August 31, 2017
    Inventors: Fajun NAN, Jia LI, Jingya LI, Mei ZHANG, Dakai CHEN, Lina ZHANG, Runtao ZHANG, Zhifu XIE
  • 2,2?-tandem dithiazole compound, preparation method therefor, and use thereof
    Patent number: 9643941
    Abstract: The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2?-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2?-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type II diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: May 9, 2017
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Jia Li, Xin Xie, Chaojun Gong, Yubo Zhou, Hui Chai, Yangming Zhang, Mingbo Su
  • NOVEL KCNQ POTASSIUM CHANNEL AGONISTS, METHOD OF PREPARATION AND METHOD OF USE THEREOF
    Publication number: 20170081301
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Application
    Filed: April 22, 2015
    Publication date: March 23, 2017
    Inventors: Fajun NAN, Min LI, Zhaobing GAO, Yangming ZHANG, Haining HU, Haiyan XU, Huanan LIU, Xiaoping PI
  • 2,2'-TANDEM DITHIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20170044119
    Abstract: The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2?-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2?-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type II diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases.
    Type: Application
    Filed: March 27, 2015
    Publication date: February 16, 2017
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun NAN, Jia LI, Xin XIE, Chaojun GONG, Yubo ZHOU, Hui CHAI, Yangming ZHANG, Mingbo SU
  • Compound as KCNQ potassium channel agonist, preparation method therefor and use thereof
    Patent number: 9353048
    Abstract: The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereofagonist, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment of nervous system diseases. The compounds or pharmaceutical compositions thereof can be used as the KCNQ potassium channel agonist for treating nervous system diseases. Compared to retigabine, a compound in the prior art, the compound of the present invention have the same or better therapeutic effect, are easier for synthesis and storage, and less prone to oxidate deterioration.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: May 31, 2016
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Fei Chen, Yangming Zhang, Pingzheng Zhou, Haining Hu, Haiyan Xu, Sheng Liu